Ethylene Oxide Residual Testing Under ISO 10993-7:2026: From Toxicological Thresholds To Analytical Verification

By Leonard Harris, Senior Scientific Advisor, Eurofins Medical Device Services

If your devices are sterilized with ethylene oxide (EtO), ISO 10993-7:2026 changes how you justify your residual acceptance criteria, and the shift is more substantive than a simple limit update. Senior Scientific Advisor Leonard Harris breaks down exactly what the revised standard requires and why it matters for sterilization validation and product release.

The core change is a stronger alignment with the toxicological risk assessment framework in ISO 10993-17. Rather than treating residual limits as material-specific thresholds, the updated standard grounds compliance in patient exposure. That means your acceptance criteria now flow from a structured three-part model: tolerable intake (TI), tolerable exposure (TE), and allowable limits (AL).

TI is derived toxicologically for both EtO and its primary reaction product ethylene chlorohydrin (ECH), normalized to body mass in mg/kg to cover adult and pediatric populations. TE then translates that into a device-specific scenario by factoring in duration of use, frequency of application, and route of administration. AL follows from TE and defines the maximum permissible residual quantity per device category, whether the contact is transient, prolonged, or long-term.

Gas chromatography-based residual measurements are then compared directly against those AL values. Without that analytical step, you have no measurable confirmation that aeration has worked. Residual testing is not optional; it is the only link between your sterilization process and demonstrated patient safety.

Access the full analysis to prepare your team for ISO 10993-7:2026 compliance before your next validation cycle.